- Home
- OGS vs IMVT Comparison
OGS vs IMVT Comparison
Compare OGS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGS
- IMVT
- Stock Information
- Founded
- OGS 1906
- IMVT N/A
- Country
- OGS United States
- IMVT United States
- Employees
- OGS N/A
- IMVT N/A
- Industry
- OGS Oil/Gas Transmission
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGS Utilities
- IMVT Health Care
- Exchange
- OGS Nasdaq
- IMVT Nasdaq
- Market Cap
- OGS 4.2B
- IMVT 4.2B
- IPO Year
- OGS N/A
- IMVT N/A
- Fundamental
- Price
- OGS $70.71
- IMVT $26.77
- Analyst Decision
- OGS Hold
- IMVT Strong Buy
- Analyst Count
- OGS 6
- IMVT 11
- Target Price
- OGS $70.92
- IMVT $48.10
- AVG Volume (30 Days)
- OGS 385.5K
- IMVT 799.9K
- Earning Date
- OGS 11-04-2024
- IMVT 02-10-2025
- Dividend Yield
- OGS 3.74%
- IMVT N/A
- EPS Growth
- OGS N/A
- IMVT N/A
- EPS
- OGS 3.82
- IMVT N/A
- Revenue
- OGS $2,058,772,000.00
- IMVT N/A
- Revenue This Year
- OGS $3.33
- IMVT N/A
- Revenue Next Year
- OGS $7.51
- IMVT N/A
- P/E Ratio
- OGS $18.46
- IMVT N/A
- Revenue Growth
- OGS N/A
- IMVT N/A
- 52 Week Low
- OGS $57.74
- IMVT $24.61
- 52 Week High
- OGS $78.89
- IMVT $45.58
- Technical
- Relative Strength Index (RSI)
- OGS 34.94
- IMVT 44.77
- Support Level
- OGS $69.85
- IMVT $26.19
- Resistance Level
- OGS $71.17
- IMVT $28.08
- Average True Range (ATR)
- OGS 1.37
- IMVT 1.01
- MACD
- OGS -0.57
- IMVT -0.03
- Stochastic Oscillator
- OGS 9.68
- IMVT 32.73
About OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).